Multi-source data-based medical temperature-adjusting atomization drug delivery system for pneumology department

Abstract

The invention discloses a multi-source data-based medical temperature-adjusting atomization drug delivery system for the pneumology department, relates to the technical field of medical temperature-adjusting atomization drug delivery, and aims to solve the problems that the atomization effect is poor and the atomization process is not intelligent. By adjusting atomization power in different respiratory cycle stages, monitoring airway abnormity and respiratory fluctuation in real time to correct parameters and adapting temperature control and atomization components as required, medicine waste and airway stimulation can be reduced, variables such as air source fluctuation and liquid medicine viscosity can be coped, atomization stability is guaranteed, administration efficiency and safety are improved, and the method is suitable for large-scale popularization and application. The requirements of patients with weak respiratory functions are met, the basic information unit is linked with the medical history of the patients and the medicine information to determine the safe temperature, the atomization rhythm is matched in combination with the respiratory parameters, temperature deviation caused by information dispersion can be avoided, manual errors are reduced, and the medication safety is improved.

Description

Technical Field

[0001] This invention relates to the field of medical temperature-controlled nebulized drug delivery technology, specifically a respiratory medical temperature-controlled nebulized drug delivery system based on multi-source data. Background Technology

[0002] Existing respiratory nebulization drug delivery systems have significant drawbacks: patient basic information and drug information are collected separately, making it difficult to coordinate and match personalized safety temperatures, and the lack of manual review can easily lead to temperature deviations; the accuracy of drug temperature control is low and the response is slow; the respiratory parameter monitoring sensors have poor compatibility and the signals are not synchronized, which can easily lead to data errors; the coordination between nebulization and respiration is insufficient, multi-source treatment data is not integrated, and abnormal feedback is delayed, making it difficult to ensure the safety and effectiveness of nebulization therapy. Summary of the Invention

[0003] The purpose of this invention is to provide a temperature-controlled nebulized drug delivery system for respiratory medicine based on multi-source data. By adjusting the nebulization power in stages of the respiratory cycle, monitoring airway abnormalities and respiratory fluctuations to correct parameters in real time, and adapting the temperature control and nebulization components as needed, it can reduce drug waste and airway irritation, cope with variables such as air source fluctuations and drug viscosity, ensure nebulization stability, improve drug delivery efficiency and safety, and meet the needs of patients with weak respiratory function. By linking patient medical history and drug information through basic information units, a safe temperature is determined, and the nebulization rhythm is matched with respiratory parameters, which can avoid temperature deviations caused by information dispersion, reduce human error, improve medication safety, and solve the problems in the prior art.

[0004] To achieve the above objectives, the present invention provides the following technical solution: A respiratory medical temperature-controlled nebulization drug delivery system based on multi-source data includes: The basic information and safe temperature confirmation unit is used to confirm the patient's basic information and the safe target temperature for the nebulized medication. Temperature control unit is used to control the temperature of the medicine liquid using semiconductor or miniature heating and cooling elements in conjunction with a high-precision temperature sensor; The respiratory parameter synchronous monitoring unit is used to collect the patient's respiratory airflow and pressure signals using miniature airflow sensors and miniature pressure sensors, and to monitor the patient's respiratory rate, tidal volume, and inspiratory-expiratory time ratio in real time. The airway abnormality monitoring unit is used to collect sound signals corresponding to the patient's cough and wheezing through a high-sensitivity microphone and to determine whether there is airway irritation. The intelligent atomization parameter adjustment unit is used to dynamically adjust the atomization rate and particle size using piezoelectric ceramic atomization components or airflow atomization components. The respiratory and nebulization coordinated drug delivery unit is used to generate power adjustment instructions for the patient's nebulization parameters based on the patient's respiratory cycle. The multi-source data fusion management unit is used to organize the patient's entire treatment process data, and to provide feedback and adjustment suggestions on the treatment data.

[0005] Preferably, the basic information and safe temperature confirmation unit is further used for: First, collect the patient's basic information and nebulized medication information from the database; The patient's basic information includes name, age, gender, weight, height, medical record number, and respiratory-related medical history. At the same time, it automatically connects to the hospital's treatment information, electronic medical records, and previous medical records. Information about nebulized medications includes the generic name of the drug, manufacturer, specifications, and batch number; Based on the patient's basic information and the characteristics of the nebulized medication, the system automatically matches the safe target temperature range for the nebulized medication. After the safe target temperature range of nebulized drugs is confirmed, it undergoes manual review. The manual review involves medical staff confirming the safe target temperature range of the nebulized drugs. After manual review and approval, the safe target temperature range for the nebulized medication for the patient is obtained.

[0006] Preferably, the temperature control unit is further configured to: The temperature sensor is installed on the inner wall of the medicine container, and at the same time, the temperature sensor collects temperature data of the medicine container at a preset frequency. The collected temperature data is compared with the safe target temperature range, and the temperature difference is judged. Specifically, if the collected temperature data is lower than the lower limit of the safe target temperature range, it is determined to be low temperature monitoring; if the collected temperature data is higher than the lower limit of the safe target temperature range, it is determined to be high temperature monitoring; if the collected temperature data is within the safe target temperature range, it is determined to be temperature compliant. Based on the temperature difference, activate semiconductor or micro heating and cooling elements to control the temperature inside the medicine container; In the heating control process: semiconductor elements or micro heating elements are installed inside the liquid medicine container, and heat is transferred to the liquid medicine through thermal conduction to raise the temperature of the liquid medicine; During cooling control: Semiconductor components or miniature cooling components are installed inside the liquid medicine container to reduce the temperature of the liquid medicine through heat absorption, while the matching miniature cooling fan is activated. During the heating or cooling process, temperature sensors are used to measure and control the temperature inside the liquid medicine container in real time.

[0007] Preferably, the respiratory parameter synchronous monitoring unit is further used for: First, embed the miniature airflow sensor in series into the tubing between the patient's breathing mask and mouthpiece and the nebulizer output end. Then, connect the miniature pressure sensor in parallel through a branch line into the tubing between the breathing mask and mouthpiece and the nebulizer output end. When a patient undergoes nebulizer treatment, a miniature airflow sensor and a miniature pressure sensor collect the airflow and pressure signals of the patient's breathing in real time. Among them, the airflow signal is based on the patient's breathing movements, capturing the changes in the speed and direction of airflow in real time; when the patient inhales, the airflow flows from the nebulizer tubing to the patient's airway, the miniature airflow sensor detects the positive flow velocity, and outputs positive current and voltage signals that change with the inhalation force; when the patient exhales, the airflow flows out of the patient's airway to the outside, the miniature airflow sensor detects the negative flow velocity, and outputs the corresponding negative electrical signal. The pressure signal is used to synchronously capture pressure fluctuations in the patient's airway and correspond them with the airflow signal. When the patient inhales, if the airway pressure is lower than atmospheric pressure, the miniature pressure sensor outputs a negative pressure signal. When the patient exhales, if the airway pressure is higher than atmospheric pressure, the miniature pressure sensor outputs a positive pressure signal. Meanwhile, the miniature airflow sensor and the miniature pressure sensor have the same acquisition frequency, and the acquired airflow and pressure signals are then converted into physical quantities. The respiratory rate, tidal volume, and ratio of inspiratory to expiratory time are calculated based on the physical quantities of airflow and pressure signals. The calculation of respiratory rate includes respiratory cycle identification, cycle count and frequency conversion; the calculation of tidal volume includes inspiratory phase definition and flow rate integral calculation; the calculation of inspiratory and expiratory time ratio includes total time of a single respiratory cycle, inspiratory time, respiratory time and inspiratory-expiratory ratio calculation. Ultimately, respiratory parameter data of the patient during the nebulization process were obtained.

[0008] Preferably, the airway abnormality monitoring unit is further configured to: Fix a high-sensitivity microphone to the outside of the patient's breathing mask or the side of the mouthpiece; When a patient undergoes nebulization therapy, a high-sensitivity microphone continuously collects sound signals at a high-frequency sampling rate. The collected sound signals are then preprocessed, including noise reduction and purification. After preprocessing, feature recognition is performed, including cough signal recognition and wheezing signal recognition. The detection features of cough signal are signal intensity peak, duration and signal onset, and the detection features of wheezing signal are frequency stability and periodic correlation. The sound signal with identified features is subjected to stimulation judgment, and the stimulation intensity is graded according to the judgment result. The stimulation intensity grading includes mild stimulation, moderate stimulation and severe stimulation. Mild stimulation is defined as 2-3 coughs within 1 minute without wheezing, and respiratory parameters fluctuating slightly; moderate stimulation is defined as 4-5 coughs within 1 minute, or brief wheezing, with wheezing lasting 10-20 seconds and respiratory rate increasing by ≥5 breaths / min; severe stimulation is defined as ≥6 coughs within 1 minute, or continuous wheezing, with wheezing lasting ≥20 seconds, tidal volume decreasing by ≥20%, accompanied by rapid breathing. Finally, the abnormal stimulation of the airway is determined.

[0009] Preferably, the intelligent atomization parameter adjustment unit is further used for: The dynamic adjustment process for piezoelectric ceramic atomizing components is as follows: First, confirm the patient's respiratory rate data, drug characteristic data, and airway abnormality monitoring data; Specifically, the respiratory rhythm matching the nebulization parameters is confirmed based on respiratory rate data; particle size and rate benchmarks are confirmed based on drug characteristic data; and dynamic adjustments are confirmed based on airway abnormality monitoring data. First, adjust the vibration frequency of the piezoelectric ceramic atomizing component according to the target particle diameter. If the particle size is reduced, increase the vibration frequency; if the particle size is increased, decrease the vibration frequency. After the vibration frequency is adjusted, the atomization rate is adjusted. If the rate is increased, the driving voltage is increased; if the rate is decreased, the driving voltage is decreased. Finally, the drug delivery speed of the infusion pump is matched according to the vibration frequency and atomization rate. The dynamic adjustment process for airflow atomizing components is as follows: First, confirm the patient's respiratory rate data, drug characteristic data, and airway abnormality monitoring data; Specifically, the respiratory intensity for airflow matching is determined based on respiratory rate data; the airflow pressure and flow rate baselines are determined based on drug characteristic data; and dynamic adjustments are determined based on airway abnormality monitoring data. Based on airflow pressure and velocity references, air velocity and particle size are synchronized. If the velocity is increased and the particle size is reduced, the airflow pressure is increased and the airflow velocity is increased; if the velocity is decreased and the particle size is increased, the airflow pressure is decreased and the airflow velocity is reduced. When the rate is increased or decreased, the opening of the liquid channel is automatically adjusted to be larger or smaller. Meanwhile, the gas source pressure is controlled during the adjustment process. If gas source pressure fluctuations are detected, the pressure valve is automatically opened and airflow is supplemented; if the patient's respiratory rate increases, the flow rate is increased and matched to the respiratory rhythm; if the viscosity of the drug solution increases, the pressure is appropriately increased. The dynamic adjustment results of the airflow atomizing component are obtained based on the control results.

[0010] Preferably, the inhalation and nebulization co-administration unit is further used for: First, confirm the patient's respiratory cycle data. In this process, the respiratory cycle signal is collected, and the respiratory cycle is divided into stages based on the characteristics of the airflow and pressure signals in the respiratory cycle signal. After the division, the stages of inhalation, mid-inhalation, end-inhalation, and exhalation are obtained. The patient's basic information, drug characteristics, airway stimulation results, nebulizer component type, and initial power baseline data are retrieved to establish the basis for power adjustment. Based on the defined breathing cycle stages and the basis for power adjustment, power adjustment commands are generated for the atomization parameters of the piezoelectric ceramic atomizing component and the airflow atomizing component. The power adjustment command is to adjust the voltage for each respiratory cycle phase. When adjusting the power, the patient's respiratory rate is monitored in real time, and fluctuations in the respiratory rate are corrected. After correction, the respiratory cycle is adjusted, and then the power adjustment command is adjusted. After the adjustment is completed, the adjustment command is generated, and the generated command is formatted and synchronized.

[0011] Preferably, the multi-source data fusion management unit is further configured to: The patient's entire treatment process data is divided into pre-treatment preparation data, dynamic data during treatment, and post-treatment summary data. The pre-treatment preparation data is obtained from the basic information and safe temperature confirmation unit; the dynamic data during treatment is obtained from the temperature control unit, the respiratory parameter synchronous monitoring unit, the airway abnormality monitoring unit, the nebulization parameter intelligent adjustment unit, and the respiratory and nebulization coordinated drug delivery unit; the post-treatment summary data includes the core treatment indicators, the summary of abnormal times, and the final parameter status. The acquired data from the entire treatment process undergoes data preprocessing, which includes data cleaning, standardization, and structured classification. The structured classification involves dividing the entire treatment process data into datasets according to data type, including basic archives, time series datasets, and time sets. The divided datasets are then subjected to fusion analysis, which includes security analysis, effectiveness analysis, and adaptability analysis. Safety analysis includes tracing the source of airway stimulation and checking parameter compliance; efficacy analysis includes assessing drug utilization efficiency and correlation with treatment effects; and fit analysis includes individual parameter fit and the effectiveness of dynamic adjustment. Based on the results of the fusion analysis, a three-level feedback system is implemented, which includes real-time feedback, treatment summary, and historical comparison. Real-time feedback includes abnormal alerts and adjustment suggestions; treatment summaries include the generation of treatment process reports and effect evaluation conclusions; historical comparisons include quality trend analysis and group characteristic summaries. Finally, adjustment suggestions are generated based on the three levels of feedback data, including suggestions for optimizing subsequent treatment parameters, improving adjustment rules, and clinical operation suggestions.

[0012] Preferably, the respiratory medical temperature-controlled nebulization drug delivery system based on multi-source data also includes a treatment effect quantitative evaluation module, used to perform the following operations: Extract patient pre-treatment preparation data, dynamic data during treatment, and post-treatment summary data from the multi-source data fusion management unit; Based on dynamic data from treatment, including respiratory rate, tidal volume, airway irritation level, and nebulization parameter adjustments, a comprehensive treatment efficacy index is calculated using the following formula:

[0013] Among them, E is the comprehensive index of treatment effect, ranging from 0 to 100, with higher values ​​indicating better treatment effect; RF is the respiratory rate stability parameter, representing the coefficient of variation of respiratory rate during treatment, in dimensionless units, calculated by dividing the standard deviation of respiratory rate by the mean respiratory rate, reflecting the stability of respiratory rhythm; TV is the tidal volume improvement parameter, representing the relative increase of the average tidal volume during treatment compared to the baseline tidal volume before treatment, in percentage units, calculated as (average tidal volume during treatment - baseline tidal volume before treatment) / baseline tidal volume before treatment × 100%, reflecting the degree of improvement in pulmonary ventilation function; AI is the airway irritation level parameter, representing the weighted average of the irritation level levels detected by the airway abnormality monitoring unit during treatment, ranging from 0 to 1. A lower value indicates milder airway irritation. It is calculated by multiplying the number of mild, moderate, and severe irritations by weights of 0.2, 0.5, and 0.8, respectively, and then summing the results. AR is the nebulization parameter adjustment effectiveness parameter, representing the ratio of the number of adjustments made by the intelligent nebulization parameter adjustment unit to the total treatment time, measured in times per minute. It reflects the dynamic response capability of the nebulization system to the patient's respiratory status. AR0 is the baseline value for the nebulization parameter adjustment effectiveness parameter, measured in times per minute. k1, k2, k3, and k4 are weights. The coefficients, representing the weighted influence of respiratory rate stability parameters, tidal volume improvement parameters, airway irritation degree parameters, and nebulization parameter adjustment effectiveness parameters, range from 0 to 1 and satisfy k1+k2+k3+k4=1. They are determined by training a machine learning model using historical treatment data. T is the actual average temperature of the medication solution during treatment, in degrees Celsius, collected by the temperature sensor of the temperature control unit. T0 is the safe target temperature of the nebulized medication, in degrees Celsius, determined by the basic information and safe temperature confirmation unit. |T-T0| is the absolute difference between the actual temperature and the target temperature, in degrees Celsius, used to quantify the impact of temperature control deviation on the treatment effect. Based on the calculated comprehensive treatment effect index E, the corresponding treatment effect level is determined by referring to the pre-set mapping relationship between the comprehensive treatment effect index and the treatment effect level. The level includes four levels: excellent, good, medium and poor. Among them, E≥80 is excellent, 60≤E≤80 is good, 40≤E≤60 is medium and E<40 is poor. The determined treatment effect level and comprehensive treatment effect index are transmitted to the multi-source data fusion management unit for real-time feedback, treatment summary and historical comparison; If the treatment effect level is medium or poor, optimization suggestions will be generated, including specific parameter suggestions for adjusting the nebulization rate, particle size or drug solution temperature, and the optimization suggestions will be pushed to the medical staff's operation interface. After treatment, the comprehensive index of treatment effectiveness and optimization suggestions are stored in the patient's treatment record for use in optimizing subsequent treatment plans and analyzing historical data.

[0014] Preferably, the respiratory medical temperature-controlled nebulization drug delivery system based on multi-source data also includes an intelligent dose optimization module for performing the following operations: The patient's basic information, including age, weight, height, respiratory-related medical history, and the characteristics of the nebulized medication, is obtained from the basic information and safe temperature confirmation unit. Dynamic data during treatment are extracted from the multi-source data fusion management unit, including respiratory rate, tidal volume, airway irritation level, and nebulization parameter adjustment data; Based on the patient's basic information and dynamic data during treatment, an individualized dosage optimization model is constructed. This model comprehensively considers the patient's physiological characteristics, respiratory status, and drug properties to generate a recommended range of nebulized drug dosages. Before treatment begins, based on the patient's weight and respiratory medical history, and in conjunction with the characteristics of the nebulized medication, an initial nebulization dose range is preset and submitted to medical staff for manual confirmation. During treatment, respiratory parameters are monitored in real time, including respiratory rate and tidal volume collected by the synchronous monitoring unit, and the degree of airway irritation detected by the airway abnormality monitoring unit. If a respiratory rate increase exceeding a preset threshold of 10 breaths / minute, a tidal volume decrease exceeding 15%, or moderate to severe airway irritation is detected, a dose adjustment mechanism is triggered. This mechanism includes: appropriately reducing the nebulization rate to minimize airway irritation based on the degree of respiratory rate increase; appropriately increasing the particle size to improve drug deposition efficiency based on the degree of tidal volume decrease; pausing nebulization for 10-20 seconds and reassessing the respiratory status based on the degree of airway irritation; during dose adjustment, real-time monitoring of the drug solution temperature to ensure it remains within the safe target temperature range; if the temperature deviates from the safe target temperature range, dose adjustment is paused and temperature control intervention by the temperature control unit is prioritized; after adjustment, a new recommended dose range is generated, and the adjusted dose parameters and the reason for adjustment are recorded in the multi-source data fusion management unit; the adjusted dose range is pushed to the healthcare worker's interface, and a corresponding power adjustment command is generated through the respiratory and nebulization co-administration unit to ensure synchronization between the nebulization parameters and the adjusted dose range. After treatment, the entire dose optimization process, including the initial dose range, the number of adjustments, the adjusted dose range, and the reasons for the adjustments, will be recorded and stored in the patient's treatment file. If the comprehensive index of treatment effect in the quantitative evaluation module is below 60, the effectiveness of dose adjustment will be further analyzed, and dose optimization suggestions for the next treatment will be generated, including the adjustment range and frequency of the recommended dose.

[0015] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. The respiratory medical temperature-controlled nebulization drug delivery system provided by the present invention determines the safe temperature by linking patient medical history and drug information through basic information units, and matches the nebulization rhythm with respiratory parameters. This can avoid temperature deviation caused by information dispersion, reduce human error, and improve medication safety. At the same time, it adapts to individual patient characteristics and drug properties, laying a precise foundation for nebulization therapy and reducing the risk of inappropriate adaptation.

[0016] 2. The respiratory medical temperature-controlled nebulization drug delivery system provided by the present invention adjusts the nebulization power according to the respiratory cycle stage, monitors airway abnormalities and respiratory fluctuations to correct parameters in real time, and adapts the temperature control and nebulization components as needed. It can reduce drug waste and airway irritation, cope with variables such as air source fluctuations and drug viscosity, ensure nebulization stability, improve drug delivery efficiency and safety, and meet the needs of patients with weak respiratory function.

[0017] 3. The respiratory medical temperature-controlled nebulized drug delivery system based on multi-source data provided by this invention integrates data from the entire treatment process and performs multi-dimensional analysis. It guides diagnosis and treatment through three-level feedback and adjustment suggestions, facilitates treatment review, provides a basis for subsequent parameter optimization and rule improvement, helps improve clinical protocols, ensures long-term treatment efficacy and standardization, and enhances the overall management level of nebulized therapy. Attached Figure Description

[0018] Figure 1 This is a schematic diagram of the respiratory medical temperature-controlled nebulizer drug delivery unit of the present invention; Figure 2 This is a schematic diagram of the respiratory medical temperature-controlled nebulization drug delivery procedure of the present invention. Detailed Implementation

[0019] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0020] To address the issues in existing technologies, such as fragmented and difficult-to-link patient and medication information collection, lack of personalized and audited safety temperature matching, inaccurate medication temperature monitoring, slow temperature control response hindering real-time intervention, and poor sensor compatibility and signal asynchrony leading to inaccurate data, thus affecting nebulization safety and synergy, please refer to [link to relevant documentation]. Figure 1 and Figure 2 This embodiment provides the following technical solution: A respiratory medical temperature-controlled nebulization drug delivery system based on multi-source data includes: The basic information and safe temperature confirmation unit is used to confirm the patient's basic information and the safe target temperature for the nebulized medication. Temperature control unit is used to control the temperature of the medicine liquid using semiconductor or miniature heating and cooling elements in conjunction with a high-precision temperature sensor; The respiratory parameter synchronous monitoring unit is used to collect the patient's respiratory airflow and pressure signals using miniature airflow sensors and miniature pressure sensors, and to monitor the patient's respiratory rate, tidal volume, and inspiratory-expiratory time ratio in real time. The airway abnormality monitoring unit is used to collect sound signals corresponding to the patient's cough and wheezing through a high-sensitivity microphone and to determine whether there is airway irritation. The intelligent atomization parameter adjustment unit is used to dynamically adjust the atomization rate and particle size using piezoelectric ceramic atomization components or airflow atomization components. The respiratory and nebulization coordinated drug delivery unit is used to generate power adjustment instructions for the patient's nebulization parameters based on the patient's respiratory cycle. The multi-source data fusion management unit is used to organize the patient's entire treatment process data, and to provide feedback and adjustment suggestions on the treatment data.

[0021] The basic information and safe temperature confirmation unit is also used for: First, collect the patient's basic information and nebulized medication information from the database; The patient's basic information includes name, age, gender, weight, height, medical record number, and respiratory-related medical history. At the same time, it automatically connects to the hospital's treatment information, electronic medical records, and previous medical records. Information about nebulized medications includes the generic name of the drug, manufacturer, specifications, and batch number; Based on the patient's basic information and the characteristics of the nebulized medication, the system automatically matches the safe target temperature range for the nebulized medication. After the safe target temperature range of nebulized drugs is confirmed, it undergoes manual review. The manual review involves medical staff confirming the safe target temperature range of the nebulized drugs. After manual review and approval, the safe target temperature range for the nebulized medication for the patient is obtained.

[0022] Specifically, it not only collects basic information such as the patient's name, age, and respiratory medical history, but also automatically connects to hospital treatment information, electronic medical records, and previous treatment records. Simultaneously, it comprehensively collects key information such as the generic name and manufacturer of the nebulized medication, ensuring that no basic data for temperature matching is omitted. This avoids safety risks caused by incomplete information and provides accurate data support for subsequent temperature matching. Combining individual patient characteristics with the properties of the nebulized medication, it automatically matches a safe target temperature range, significantly improving the efficiency of temperature determination, reducing the workload of manual calculations and queries for medical staff, and avoiding errors from human experience-based judgment, thus ensuring accurate temperature matching. To better meet individual patient needs and ensure medication suitability, an additional manual review process by medical staff is added after automatic matching, forming a dual defense of "automatic system matching + professional manual verification." This allows for timely detection of potential data deviations or special circumstances in the system, further ensuring the accuracy of the safe target temperature range and reducing medication risks. From data collection and automatic matching to manual review and approval, a complete closed-loop management system is formed. The standardized operating procedures improve the standardization and traceability of the temperature confirmation process before nebulization treatment, providing reliable assurance for the safe conduct of clinical diagnosis and treatment, and facilitating subsequent supervision and review of medical quality.

[0023] The temperature control unit is also used for: The temperature sensor is installed on the inner wall of the medicine container, and at the same time, the temperature sensor collects temperature data of the medicine container at a preset frequency. The collected temperature data is compared with the safe target temperature range, and the temperature difference is judged. Specifically, if the collected temperature data is lower than the lower limit of the safe target temperature range, it is determined to be low temperature monitoring; if the collected temperature data is higher than the lower limit of the safe target temperature range, it is determined to be high temperature monitoring; if the collected temperature data is within the safe target temperature range, it is determined to be temperature compliant. Based on the temperature difference, activate semiconductor or micro heating and cooling elements to control the temperature inside the medicine container; In the heating control process: semiconductor elements or micro heating elements are installed inside the liquid medicine container, and heat is transferred to the liquid medicine through thermal conduction to raise the temperature of the liquid medicine; During cooling control: Semiconductor components or miniature cooling components are installed inside the liquid medicine container to reduce the temperature of the liquid medicine through heat absorption, while the matching miniature cooling fan is activated. During the heating or cooling process, temperature sensors are used to measure and control the temperature inside the liquid medicine container in real time.

[0024] Specifically, the temperature sensor is directly installed on the inner wall of the liquid medicine container, enabling it to directly sense the true temperature of the liquid medicine and avoid measurement deviations caused by external environmental interference. Simultaneously, it collects data at a preset frequency to ensure real-time capture of liquid medicine temperature changes, providing accurate and timely data for subsequent temperature control. By comparing the collected temperature with the safety target range, it clearly classifies three states: low temperature, high temperature, and compliant, with no ambiguous judgment intervals. This allows for rapid and accurate identification of abnormal temperature types, providing clear guidance for targeted temperature control measures and avoiding delays due to ambiguous judgments. It employs semiconductor or micro-temperature control elements with built-in installation, acting directly on the liquid medicine through heat conduction / absorption, resulting in fast and efficient temperature control response. During cooling, a micro-cooling fan is simultaneously activated to solve the heat dissipation problem of the cooling element, ensuring stable cooling performance and meeting the refined requirements of liquid medicine temperature control. During heating or cooling, the temperature sensor continuously measures and intervenes in real time, forming a closed-loop management system of "collection-judgment-control-re-monitoring." This system can promptly correct temperature control deviations, prevent temperature overshoot or failure to reach the target, and ensure that the liquid medicine temperature is stably maintained within a safe range, guaranteeing the safety of nebulized medication use.

[0025] The respiratory parameter synchronous monitoring unit is also used for: First, embed the miniature airflow sensor in series into the tubing between the patient's breathing mask and mouthpiece and the nebulizer output end. Then, connect the miniature pressure sensor in parallel through a branch line into the tubing between the breathing mask and mouthpiece and the nebulizer output end. When a patient undergoes nebulizer treatment, a miniature airflow sensor and a miniature pressure sensor collect the airflow and pressure signals of the patient's breathing in real time. Among them, the airflow signal is based on the patient's breathing movements, capturing the changes in the speed and direction of airflow in real time; when the patient inhales, the airflow flows from the nebulizer tubing to the patient's airway, the miniature airflow sensor detects the positive flow velocity, and outputs positive current and voltage signals that change with the inhalation force; when the patient exhales, the airflow flows out of the patient's airway to the outside, the miniature airflow sensor detects the negative flow velocity, and outputs the corresponding negative electrical signal. The pressure signal is used to synchronously capture pressure fluctuations in the patient's airway and correspond them with the airflow signal. When the patient inhales, if the airway pressure is lower than atmospheric pressure, the miniature pressure sensor outputs a negative pressure signal. When the patient exhales, if the airway pressure is higher than atmospheric pressure, the miniature pressure sensor outputs a positive pressure signal. Meanwhile, the miniature airflow sensor and the miniature pressure sensor have the same acquisition frequency, and the acquired airflow and pressure signals are then converted into physical quantities. The respiratory rate, tidal volume, and ratio of inspiratory to expiratory time are calculated based on the physical quantities of airflow and pressure signals. The calculation of respiratory rate includes respiratory cycle identification, cycle count and frequency conversion; the calculation of tidal volume includes inspiratory phase definition and flow rate integral calculation; the calculation of inspiratory and expiratory time ratio includes total time of a single respiratory cycle, inspiratory time, respiratory time and inspiratory-expiratory ratio calculation. Ultimately, respiratory parameter data of the patient during the nebulization process were obtained.

[0026] Specifically, a miniature airflow sensor is embedded in series in the tubing, while a pressure sensor is connected in parallel via a branch tubing. This eliminates the need to modify the core structure of the existing nebulizer, avoiding damage to the tubing's seal and ensuring uninterrupted nebulized airflow delivery, thus guaranteeing normal nebulization treatment for patients. It is compatible with existing breathing masks, mouthpieces, and other common accessories, making it suitable for a wide range of scenarios. The airflow sensor can distinguish between positive inspiratory flow and negative expiratory flow, outputting corresponding positive and negative electrical signals to accurately capture airflow changes. The pressure sensor simultaneously identifies negative inspiratory pressure below atmospheric pressure and positive expiratory pressure above atmospheric pressure within the airway, achieving a precise correspondence between airflow, pressure signals, and respiratory actions. This provides high-quality raw data for subsequent parameter calculations. The force sensor's consistent acquisition frequency avoids data deviations caused by asynchronous acquisition and accurately converts electrical signals into physical quantities, ensuring a high degree of matching between the two key data points in the time dimension. This lays a reliable foundation for respiratory parameter calculation, enabling the calculation of respiratory rate, tidal volume, and inspiratory-expiratory time ratio, comprehensively reflecting the patient's respiratory function status during nebulization. This meets the core clinical needs for respiratory parameter monitoring, allowing for real-time acquisition of respiratory parameter data. Medical staff can promptly assess whether the patient's respiratory rate is normal, tidal volume is within the target range, and inspiratory-expiratory ratio is appropriate. Especially for children, the elderly, and other patients with weaker respiratory function, the nebulization regimen can be adjusted in a timely manner, reducing treatment risks and improving the safety and effectiveness of nebulization therapy.

[0027] To address the issues in existing technologies, such as the susceptibility of airway abnormality monitoring to interference leading to inaccurate cough and wheezing identification and ambiguous stimulation grading; and the lack of integration of respiratory, medication, and airway data in nebulizer parameter adjustment resulting in poor dynamic adaptation and parameter instability due to gas source fluctuations or drug viscosity, which can reduce efficacy or increase airway irritation, please refer to [the relevant documentation / reference]. Figure 1 and Figure 2 This embodiment provides the following technical solution: The airway abnormality monitoring unit is also used for: Fix a high-sensitivity microphone to the outside of the patient's breathing mask or the side of the mouthpiece; When a patient undergoes nebulization therapy, a high-sensitivity microphone continuously collects sound signals at a high-frequency sampling rate. The collected sound signals are then preprocessed, including noise reduction and purification. After preprocessing, feature recognition is performed, including cough signal recognition and wheezing signal recognition. The detection features of cough signal are signal intensity peak, duration and signal onset, and the detection features of wheezing signal are frequency stability and periodic correlation. The sound signal with identified features is subjected to stimulation judgment, and the stimulation intensity is graded according to the judgment result. The stimulation intensity grading includes mild stimulation, moderate stimulation and severe stimulation. Mild stimulation is defined as 2-3 coughs within 1 minute without wheezing, and respiratory parameters fluctuating slightly; moderate stimulation is defined as 4-5 coughs within 1 minute, or brief wheezing, with wheezing lasting 10-20 seconds and respiratory rate increasing by ≥5 breaths / min; severe stimulation is defined as ≥6 coughs within 1 minute, or continuous wheezing, with wheezing lasting ≥20 seconds, tidal volume decreasing by ≥20%, accompanied by rapid breathing. Finally, the abnormal stimulation of the airway is determined.

[0028] Specifically, the high-sensitivity microphone is fixed to the outside of the mask or next to the mouthpiece, without intruding into the patient's airway, thus avoiding obstruction of breathing and preserving the seal and airflow of the nebulization tubing. It is compatible with existing nebulization equipment accessories, adaptable to different patient scenarios, and does not affect the normal nebulization treatment process, ensuring high safety. It acquires sound signals at a high sampling rate, combined with noise reduction and purification preprocessing, effectively filtering out environmental noise and retaining clear, original airway sound data. During feature recognition, specific detection dimensions are set for cough and wheezing, ensuring accurate differentiation between these two types of abnormal signals and providing high-quality evidence for subsequent judgment. The severity grading system combines cough frequency, wheezing duration, and changes in respiratory parameters, with clear thresholds for mild to severe irritation to avoid ambiguity. Healthcare professionals can quickly assess the severity of airway abnormalities based on the grading, improving response efficiency. Monitoring relies not only on sound signals but also on fluctuations in respiratory parameters, forming a dual-dimensional assessment system of "sound + respiration," reducing the risk of misjudgment based on a single indicator. Real-time capture and grading of abnormalities promptly alerts healthcare professionals to intervene, reducing the risk of worsening airway irritation, helping to optimize treatment plans, and ensuring the safety of nebulization therapy. The table below shows the airway irritation severity grading and corresponding parameter thresholds:

[0029] The intelligent atomization parameter adjustment unit is also used for: The dynamic adjustment process for piezoelectric ceramic atomizing components is as follows: First, confirm the patient's respiratory rate data, drug characteristic data, and airway abnormality monitoring data; Specifically, the respiratory rhythm matching the nebulization parameters is confirmed based on respiratory rate data; particle size and rate benchmarks are confirmed based on drug characteristic data; and dynamic adjustments are confirmed based on airway abnormality monitoring data. First, adjust the vibration frequency of the piezoelectric ceramic atomizing component according to the target particle diameter. If the particle size is reduced, increase the vibration frequency; if the particle size is increased, decrease the vibration frequency. After the vibration frequency is adjusted, the atomization rate is adjusted. If the rate is increased, the driving voltage is increased; if the rate is decreased, the driving voltage is decreased. Finally, the drug delivery speed of the infusion pump is matched according to the vibration frequency and atomization rate. The dynamic adjustment process for airflow atomizing components is as follows: First, confirm the patient's respiratory rate data, drug characteristic data, and airway abnormality monitoring data; Specifically, the respiratory intensity for airflow matching is determined based on respiratory rate data; the airflow pressure and flow rate baselines are determined based on drug characteristic data; and dynamic adjustments are determined based on airway abnormality monitoring data. Based on airflow pressure and velocity references, air velocity and particle size are synchronized. If the velocity is increased and the particle size is reduced, the airflow pressure is increased and the airflow velocity is increased; if the velocity is decreased and the particle size is increased, the airflow pressure is decreased and the airflow velocity is reduced. When the rate is increased or decreased, the opening of the liquid channel is automatically adjusted to be larger or smaller. Meanwhile, the gas source pressure is controlled during the adjustment process. If gas source pressure fluctuations are detected, the pressure valve is automatically opened and airflow is supplemented; if the patient's respiratory rate increases, the flow rate is increased and matched to the respiratory rhythm; if the viscosity of the drug solution increases, the pressure is appropriately increased. The dynamic adjustment results of the airflow atomizing component are obtained based on the control results.

[0030] Specifically, based on respiratory rate, drug characteristics, and airway abnormalities, this approach avoids biases caused by single data points and ensures that adjustments are tailored to the patient's respiratory status and medication needs. It improves nebulization adaptability from the outset, designing processes for two main types of nebulizer components: piezoelectric ceramic and airflow-based. Piezoelectric ceramic nebulizers are adjusted via vibration frequency and driving voltage, while airflow-based nebulizers are adjusted via pressure, flow rate, and channel opening. This ensures compatibility with different device types, meets diverse clinical needs, and provides clear parameter adjustments that can respond to variables in real time. This avoids the inefficiency caused by fixed parameters and guarantees nebulization stability. From data confirmation to parameter adjustment, minimal manual intervention is required, reducing the workload of medical staff and avoiding human error. This approach is particularly suitable for busy clinical scenarios, balancing efficiency and safety.

[0031] To address the shortcomings of existing technologies, such as insufficient coordination between respiration and nebulization, difficulty in matching parameters to the respiratory cycle leading to drug waste or airway irritation, fragmented and unintegrated multi-source treatment data hindering systematic analysis and feedback, lack of personalized parameter adjustment resulting in poor adaptability, and delayed safety monitoring and feedback, ultimately leading to low overall treatment efficacy and safety, please refer to [the relevant documentation / reference]. Figure 1 and Figure 2 This embodiment provides the following technical solution: The combined respiratory and nebulization drug delivery unit is also used for: First, confirm the patient's respiratory cycle data. In this process, the respiratory cycle signal is collected, and the respiratory cycle is divided into stages based on the characteristics of the airflow and pressure signals in the respiratory cycle signal. After the division, the stages of inhalation, mid-inhalation, end-inhalation, and exhalation are obtained. The patient's basic information, drug characteristics, airway stimulation results, nebulizer component type, and initial power baseline data are retrieved to establish the basis for power adjustment. Based on the defined breathing cycle stages and the basis for power adjustment, power adjustment commands are generated for the atomization parameters of the piezoelectric ceramic atomizing component and the airflow atomizing component. The power adjustment command is to adjust the voltage for each respiratory cycle phase. When adjusting the power, the patient's respiratory rate is monitored in real time, and fluctuations in the respiratory rate are corrected. After correction, the respiratory cycle is adjusted, and then the power adjustment command is adjusted. After the adjustment is completed, the adjustment command is generated, and the generated command is formatted and synchronized.

[0032] Specifically, the respiratory cycle is divided into early, middle, and late inspiration and expiration. Nebulizer power can be adjusted for different stages. For example, during mid-inspiration, power can be increased as needed to enhance drug delivery, while during expiration, power can be reduced to minimize waste. This achieves precise synchronization between drug administration and respiratory rhythm, improving drug utilization and reducing ineffective airway stimulation. By retrieving patient information, drug characteristics, airway stimulation results, and nebulizer component type, a comprehensive power adjustment basis can be constructed, adapting to different patients, drugs, and components. This avoids a "one-size-fits-all" approach, meeting personalized drug administration needs, improving treatment safety, and allowing for real-time monitoring of respiratory rate. If fluctuations occur, timely correction and adjustment can be implemented. Inhalation cycle and power commands prevent dosing deviations caused by unstable patient breathing, making it especially suitable for patients with weak respiratory function and fluctuating respiratory rates. It ensures dosing stability and generates power adjustment commands for both piezoelectric ceramic and airflow nebulizer components without requiring the replacement of the monitoring unit. It is compatible with existing mainstream nebulizer devices, reducing clinical equipment replacement costs and adapting to the nebulization needs of different treatment scenarios. After generating adjustment commands, the format is adapted and synchronized to ensure that the commands are accurately matched with the nebulizer components and transmitted in a timely manner. This avoids dosing errors caused by incompatible command formats or delays, ensuring that nebulized drug delivery is executed efficiently according to the adjustment plan and facilitating the orderly conduct of clinical treatment.

[0033] The multi-source data fusion management unit is also used for: The patient's entire treatment process data is divided into pre-treatment preparation data, dynamic data during treatment, and post-treatment summary data. The pre-treatment preparation data is obtained from the basic information and safe temperature confirmation unit; the dynamic data during treatment is obtained from the temperature control unit, the respiratory parameter synchronous monitoring unit, the airway abnormality monitoring unit, the nebulization parameter intelligent adjustment unit, and the respiratory and nebulization coordinated drug delivery unit; the post-treatment summary data includes the core treatment indicators, the summary of abnormal times, and the final parameter status. The acquired data from the entire treatment process undergoes data preprocessing, which includes data cleaning, standardization, and structured classification. The structured classification involves dividing the entire treatment process data into datasets according to data type, including basic archives, time series datasets, and time sets. The divided datasets are then subjected to fusion analysis, which includes security analysis, effectiveness analysis, and adaptability analysis. Safety analysis includes tracing the source of airway stimulation and checking parameter compliance; efficacy analysis includes assessing drug utilization efficiency and correlation with treatment effects; and fit analysis includes individual parameter fit and the effectiveness of dynamic adjustment. Based on the results of the fusion analysis, a three-level feedback system is implemented, which includes real-time feedback, treatment summary, and historical comparison. Real-time feedback includes abnormal alerts and adjustment suggestions; treatment summaries include the generation of treatment process reports and effect evaluation conclusions; historical comparisons include quality trend analysis and group characteristic summaries. Finally, adjustment suggestions are generated based on the three levels of feedback data, including suggestions for optimizing subsequent treatment parameters, improving adjustment rules, and clinical operation suggestions.

[0034] Specifically, the data is divided into pre-treatment, during-treatment, and post-treatment phases, comprehensively integrating information from the entire nebulization treatment cycle. This avoids data fragmentation and provides a complete basis for diagnosis and treatment evaluation. Through cleaning, standardization, and structured classification, the accuracy and usability of the data are improved, avoiding interference from messy data and laying a reliable foundation for subsequent fusion analysis. This includes safety, efficacy, and suitability analysis, providing multi-dimensional assessment of treatment, ensuring safety while verifying efficacy and suitability. Real-time feedback allows for timely abnormal warnings and adjustment suggestions, assisting medical staff in rapid intervention. Treatment summaries generate reports and effect conclusions, facilitating treatment review. Historical comparative analysis of quality trends and group characteristics supports long-term treatment optimization to meet different clinical needs. Based on feedback, subsequent treatment parameter optimization, adjustment rule improvement, and clinical operation suggestions are generated, directly guiding subsequent diagnosis and treatment, helping medical staff to accurately adjust plans, and improving the standardization and effectiveness of nebulization treatment.

[0035] The respiratory medical temperature-controlled nebulizer drug delivery system based on multi-source data also includes a treatment efficacy quantitative evaluation module, used to perform the following operations: Extract patient pre-treatment preparation data, dynamic data during treatment, and post-treatment summary data from the multi-source data fusion management unit; Based on dynamic data from treatment, including respiratory rate, tidal volume, airway irritation level, and nebulization parameter adjustments, a comprehensive treatment efficacy index is calculated using the following formula:

[0036] Among them, E is the comprehensive index of treatment effect, ranging from 0 to 100, with higher values ​​indicating better treatment effect; RF is the respiratory rate stability parameter, representing the coefficient of variation of respiratory rate during treatment, in dimensionless units, calculated by dividing the standard deviation of respiratory rate by the mean respiratory rate, reflecting the stability of respiratory rhythm; TV is the tidal volume improvement parameter, representing the relative increase of the average tidal volume during treatment compared to the baseline tidal volume before treatment, in percentage units, calculated as (average tidal volume during treatment - baseline tidal volume before treatment) / baseline tidal volume before treatment × 100%, reflecting the degree of improvement in pulmonary ventilation function; AI is the airway irritation level parameter, representing the weighted average of the irritation level levels detected by the airway abnormality monitoring unit during treatment, ranging from 0 to 1. A lower value indicates milder airway irritation. It is calculated by multiplying the number of mild, moderate, and severe irritations by weights of 0.2, 0.5, and 0.8, respectively, and then summing the results. AR is the nebulization parameter adjustment effectiveness parameter, representing the ratio of the number of adjustments made by the intelligent nebulization parameter adjustment unit to the total treatment time, measured in times per minute. It reflects the dynamic response capability of the nebulization system to the patient's respiratory status. AR0 is the baseline value for the nebulization parameter adjustment effectiveness parameter, measured in times per minute. k1, k2, k3, and k4 are weights. The coefficients, representing the weighted influence of respiratory rate stability parameters, tidal volume improvement parameters, airway irritation degree parameters, and nebulization parameter adjustment effectiveness parameters, range from 0 to 1 and satisfy k1+k2+k3+k4=1. They are determined by training a machine learning model using historical treatment data. T is the actual average temperature of the medication solution during treatment, in degrees Celsius, collected by the temperature sensor of the temperature control unit. T0 is the safe target temperature of the nebulized medication, in degrees Celsius, determined by the basic information and safe temperature confirmation unit. |T-T0| is the absolute difference between the actual temperature and the target temperature, in degrees Celsius, used to quantify the impact of temperature control deviation on the treatment effect. Based on the calculated comprehensive treatment effect index E, the corresponding treatment effect level is determined by referring to the pre-set mapping relationship between the comprehensive treatment effect index and the treatment effect level. The level includes four levels: excellent, good, medium and poor. Among them, E≥80 is excellent, 60≤E≤80 is good, 40≤E≤60 is medium and E<40 is poor. The determined treatment effect level and comprehensive treatment effect index are transmitted to the multi-source data fusion management unit for real-time feedback, treatment summary and historical comparison; If the treatment effect level is medium or poor, optimization suggestions will be generated, including specific parameter suggestions for adjusting the nebulization rate, particle size or drug solution temperature, and the optimization suggestions will be pushed to the medical staff's operation interface. After treatment, the comprehensive index of treatment effectiveness and optimization suggestions are stored in the patient's treatment record for use in optimizing subsequent treatment plans and analyzing historical data.

[0037] The working principle and beneficial effects of the above technical solution are as follows: The treatment efficacy quantitative evaluation module extracts pre-treatment preparation data (such as patient basic information and nebulized drug characteristics), dynamic data during treatment (such as respiratory rate, tidal volume, airway stimulation level, and nebulization parameter adjustment data), and post-treatment summary data (such as core treatment indicators and abnormal time summaries) from the multi-source data fusion management unit to systematically evaluate treatment efficacy. The core of this evaluation is the calculation of the comprehensive treatment efficacy index E, using the formula: The parameters are defined as follows: RF (Respiratory Rate Stability Parameter) is a dimensionless value, calculated by the ratio of its standard deviation to the mean (standard deviation / mean respiratory rate) based on respiratory rate data collected from the respiratory parameter synchronous monitoring unit during treatment, reflecting the stability of respiratory rhythm; TV (Tidal Volume Improvement Parameter) is a percentage, calculated as (mean tidal volume during treatment - baseline tidal volume before treatment) / baseline tidal volume before treatment × 100%, obtained from tidal volume data during treatment through the respiratory parameter synchronous monitoring unit, and the baseline tidal volume extracted from pre-treatment preparation data; AI (Airway Stimulation Level Parameter) ranges from 0 to 1, calculated by weighted summation of mild (weight 0.2), moderate (weight 0.5), and severe (weight 0.8) stimulation times recorded by the airway abnormality monitoring unit, with weights preset based on clinical experience and stored in the database; AR (Nebulization Parameter Adjustment Effectiveness Parameter) The value is calculated as times / minute, calculated by dividing the number of adjustments made by the intelligent adjustment unit of the nebulization parameters during treatment by the total treatment time. This value is extracted from the multi-source data fusion management unit. AR0 is the baseline value of the nebulization parameter adjustment effectiveness parameter, measured in times / minute, and can be preset by technicians. k1, k2, k3, and k4 are weighting coefficients (ranging from 0 to 1, satisfying k1+k2+k3+k4=1), generated by training a machine learning model (such as random forest or neural network) using historical treatment data (obtained from the multi-source data fusion management unit) and stored in the system database. T is the actual average temperature of the medicine solution during treatment (degrees Celsius), collected and averaged by the temperature sensor of the temperature control unit at a preset frequency (e.g., once per second). T0 is the safe target temperature (degrees Celsius), obtained from the basic information and safe temperature confirmation unit. |T-T0| is the absolute value of the temperature deviation, used to quantify the impact of temperature control. After calculating E, the treatment effect level is determined by comparing it with a preset mapping relationship (E≥80 is excellent, 60≤E≤80 is good, 40≤E≤60 is moderate, and E<40 is poor). The level and E value are then transmitted back to the multi-source data fusion management unit for real-time feedback (abnormal warnings, adjustment suggestions), treatment summary (report generation, effect conclusions), and historical comparison (quality trends, group characteristics). If the level is moderate or poor, the system generates optimization suggestions based on respiratory rate, tidal volume, airway stimulation degree, and nebulization parameter data (such as reducing the nebulization rate by 5%, increasing the particle diameter by 0.5μm, and adjusting the drug solution temperature to T0±0.5℃), and pushes this to the medical staff's interface. After treatment, the E value and suggestions are stored in the patient's treatment file (database) to support subsequent optimization and analysis.

[0038] For example, based on treatment data of a 65-year-old COPD patient using budesonide nebulizer, the system first calculates various parameters: respiratory rate stability (RF) (2 / 18≈0.11), tidal volume improvement (TV) ((450-400) / 400×100%=12.5%), airway irritation level (AI) (2×0.2=0.4), and nebulizer adjustment effectiveness (AR) (3 / 10=0.3 times / minute); then, combined with the baseline adjustment frequency AR0 (0.2 times / minute) determined from historical data, the relative ratio AR / AR0=1.5 is obtained, and the relative temperature deviation |T-T0| / T0 (0.5 / 25=0.02) is calculated; substituting the weights (k1-4 are 0.3, 0.3, 0.2, 0.2 respectively), the comprehensive formula is E=[0.3×0.1]. [1+0.3×0.125+0.2×(1-0.4)+0.2×1.5] / (1+0.02)≈0.4905 / 1.02≈0.4809, after amplification, the comprehensive treatment effect index E=48.09 (medium level); after the result was returned, the system generated real-time feedback suggesting that the current parameters be maintained. The treatment summary indicated that the tidal volume had improved well but was accompanied by slight irritation. Historical comparison showed that the value was at the average level of the group. Since the E value did not reach the excellent level, the system analysis found that the adjustment frequency was too high and there was slight irritation. Therefore, the optimization suggestion was generated: "The nebulization rate can be slightly reduced or the particle diameter can be increased to 3μm to reduce irritation." After the medical staff confirmed the suggestion, the parameters were adjusted. Finally, all data and suggestions were stored in the patient's file with the medical record number and timestamp as the primary key for subsequent treatment reference and long-term analysis.

[0039] The respiratory medical temperature-controlled nebulized drug delivery system based on multi-source data also includes an intelligent dose optimization module, which performs the following operations: The patient's basic information, including age, weight, height, respiratory-related medical history, and the characteristics of the nebulized medication, is obtained from the basic information and safe temperature confirmation unit. Dynamic data during treatment are extracted from the multi-source data fusion management unit, including respiratory rate, tidal volume, airway irritation level, and nebulization parameter adjustment data; Based on the patient's basic information and dynamic data during treatment, an individualized dosage optimization model is constructed. This model comprehensively considers the patient's physiological characteristics, respiratory status, and drug properties to generate a recommended range of nebulized drug dosages. Before treatment begins, based on the patient's weight and respiratory medical history, and in conjunction with the characteristics of the nebulized medication, an initial nebulization dose range is preset and submitted to medical staff for manual confirmation. During treatment, respiratory parameters are monitored in real time, including respiratory rate and tidal volume collected by the synchronous monitoring unit, and the degree of airway irritation detected by the airway abnormality monitoring unit. If a respiratory rate increase exceeding a preset threshold of 10 breaths / minute, a tidal volume decrease exceeding 15%, or moderate to severe airway irritation is detected, a dose adjustment mechanism is triggered. This mechanism includes: appropriately reducing the nebulization rate to minimize airway irritation based on the degree of respiratory rate increase; appropriately increasing the particle size to improve drug deposition efficiency based on the degree of tidal volume decrease; pausing nebulization for 10-20 seconds and reassessing the respiratory status based on the degree of airway irritation; during dose adjustment, real-time monitoring of the drug solution temperature to ensure it remains within the safe target temperature range; if the temperature deviates from the safe target temperature range, dose adjustment is paused and temperature control intervention by the temperature control unit is prioritized; after adjustment, a new recommended dose range is generated, and the adjusted dose parameters and the reason for adjustment are recorded in the multi-source data fusion management unit; the adjusted dose range is pushed to the healthcare worker's interface, and a corresponding power adjustment command is generated through the respiratory and nebulization co-administration unit to ensure synchronization between the nebulization parameters and the adjusted dose range. After treatment, the entire dose optimization process, including the initial dose range, the number of adjustments, the adjusted dose range, and the reasons for the adjustments, will be recorded and stored in the patient's treatment file. If the comprehensive index of treatment effect in the quantitative evaluation module is below 60, the effectiveness of dose adjustment will be further analyzed, and dose optimization suggestions for the next treatment will be generated, including the adjustment range and frequency of the recommended dose.

[0040] The working principle and beneficial effects of the above technical solution are as follows: The intelligent dosage optimization module integrates basic patient information (age, weight, height, respiratory history, nebulized drug characteristics) and dynamic data during treatment (respiratory rate, tidal volume, airway irritation level, nebulization parameter adjustment data) to construct an individualized dosage optimization model and generate a recommended nebulized drug dosage range. Basic information is obtained from the basic information and safe temperature confirmation unit, including patient records (name, age, weight, height, medical record number, respiratory history) and drug information (generic name, manufacturer, specifications, batch number), extracted through database queries or the hospital's electronic medical record system interface (HL7 standard). Dynamic data during treatment is obtained from the multi-source data fusion management unit, including respiratory rate (breaths / minute, collected by a miniature airflow sensor) and tidal volume (mL, calculated by flow rate integral) from the respiratory parameter synchronous monitoring unit, irritation level (mild / moderate / severe, microphone signal analysis) from the airway abnormality monitoring unit, and nebulization parameter adjustment data (adjustment times / minute, recorded by the intelligent nebulization parameter adjustment unit). The model presets an initial dose range based on patient weight (mg / kg baseline), medical history (COPD adjustment factor +10%), and drug characteristics (recommended dose range, such as budesonide 0.5-2 mg / dose). This range is then submitted to healthcare professionals for manual confirmation via an interface (touchscreen or web interface). During treatment, respiratory rate (threshold increase of 10 breaths / min), tidal volume (decrease of 15%), and airway stimulation (moderate / severe, weighted 0.5 / 0.8) are monitored in real time. If the adjustment mechanism is triggered, the nebulization rate is reduced (e.g., reduced by 10%) based on the degree of increase in respiratory rate, the particle diameter is increased (e.g., +0.5 μm) based on the decrease in tidal volume, and nebulization is paused for 10-20 seconds (timer-controlled, 1ms accuracy) for airway stimulation, followed by reassessment (collecting the latest respiratory data). During adjustment, the temperature control unit monitors the drug solution temperature in real time (sensor frequency 1Hz). If the temperature deviates from the safe target temperature range (e.g., 25±1℃), dose adjustment is paused (temperature control intervention is prioritized, with heating / cooling power adjusted ±10W). After adjustment, a new dosage range (e.g., 0.8-1.2 mg) is generated, and the adjustment parameters and reasons are recorded in the multi-source data fusion management unit and pushed to the medical staff interface (JSON format notification). After treatment, the initial dose, number of adjustments, new dosage range, and reasons are stored in the treatment file (database table: treatmentlog). If the comprehensive treatment effect index E < 60 (obtained from the treatment effect quantitative assessment module), the effectiveness of the adjustment is analyzed (comparing changes in respiratory parameters before and after the adjustment; for example, a tidal volume increase of < 5% is considered ineffective), and suggestions for the next treatment are generated (e.g., increasing the dose by 0.2 mg or reducing the adjustment frequency to 0.2 times / minute).

[0041] Taking a 65-year-old, 70kg COPD patient as an example, when administering budesonide (1mg / 2mL, safe temperature 25℃), the intelligent dose optimization module first extracts patient data (age 65, 70kg, height 170cm, COPD history 10 years, budesonide characteristics: recommended dose 0.5-2mg / dose) from the basic information and safe temperature confirmation unit, and obtains it through SQL query and HL7 interface; it then extracts dynamic data (initial respiratory rate 18 breaths / min, tidal volume 400mL, 2 mild stimulations, 3 adjustments / 10 minutes) from the multi-source data fusion management unit. The model presets an initial dose of 0.9-1.2mg based on weight (0.015mg / kg, 1.05mg for 70kg) and COPD history (+10%), which is confirmed by medical staff through the web interface (displaying "Initial dose: 0.9-1.2mg, confirm?"). During treatment, the miniature airflow sensor detected a respiratory rate increase to 30 breaths / min (threshold 18+10=28), triggering an adjustment mechanism: reducing the nebulization rate by 10% (from 2 mL / min to 1.8 mL / min, adjusting the drive voltage to -5V); decreasing the tidal volume to 340 mL (a 15% decrease, 400×0.85=340); increasing the particle diameter by 0.5 μm (reducing the vibration frequency by 100 Hz); detecting moderate stimulation (1 instance, weight 0.5), nebulization was paused for 15 seconds (timer controlled), and after reassessment, the respiratory rate decreased to 25 breaths / min. The temperature sensor monitored the drug solution temperature at 25.2℃ (within 25±1℃), requiring no temperature control intervention. The new dosage range was adjusted to 0.8-1.1 mg, logged to the multi-source data fusion management unit, and pushed to the healthcare interface. The respiratory and nebulization co-administration unit generated a power adjustment command (voltage -5V, executed synchronously). At the end of treatment, record the initial dose of 0.9-1.2 mg, the dose adjusted twice, the new dose of 0.8-1.1 mg, and the reason for the adjustment in the treatment record. Since E=62 (obtained from the treatment efficacy quantitative assessment module), no further optimization is required, but it is recommended that the maintenance dose for the next treatment be 0.8-1.1 mg, with an adjustment frequency of 0.3 times / minute, and save the record for subsequent optimization.

[0042] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0043] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention.

Claims

1. A respiratory medical temperature-adjusted nebulization administration system based on multi-source data, characterized in that, The system comprises: a basic information and safe temperature confirmation unit for confirming patient basic information and aerosol medicine safe target temperature; a temperature control unit for controlling medicine liquid temperature by using semiconductor or micro heating and refrigeration elements in cooperation with high-precision temperature sensors; a respiratory parameter synchronous monitoring unit for collecting patient respiratory airflow and pressure signals by using micro airflow sensors and micro pressure sensors, and for monitoring respiratory frequency, tidal volume and inspiration and expiration time ratio in real time; an airway abnormality monitoring unit for collecting patient cough and wheeze sound signals by using high-sensitivity microphones, and for judging airway irritation; an aerosol parameter intelligent adjustment unit for dynamically adjusting aerosol rate and particle size by using piezoelectric ceramic aerosol components or airflow type aerosol components; a respiratory and aerosol coordinated administration unit for generating aerosol parameter power adjustment instructions according to patient respiratory cycle; a multi-source data fusion management unit for arranging patient whole treatment process data, and for making treatment data feedback and adjustment suggestions; a treatment effect quantitative evaluation module for: extracting patient pre-treatment preparation data, treatment dynamic data and post-treatment summary data from the multi-source data fusion management unit, and for calculating a treatment effect comprehensive index based on respiratory frequency, tidal volume, airway irritation degree and aerosol parameter adjustment data in the treatment dynamic data.

2. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 1, wherein, The basic information and safe temperature confirmation unit is also used for: collecting patient basic information and aerosol medicine information from a database; wherein the patient basic information comprises name, age, gender, weight, height, medical record number and respiratory department related medical history, and is automatically connected to hospital treatment information, electronic medical record and previous diagnosis and treatment records; the aerosol medicine information comprises drug generic name, manufacturer, specification and drug lot number; the patient corresponding aerosol medicine safe target temperature range is determined after the temperature range is manually reviewed and qualified by medical staff in combination with the patient basic information and aerosol medicine characteristics.

3. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 2, characterized in that, The temperature control unit is also used for: installing the temperature sensor on the inner wall of the medicine liquid container, collecting medicine liquid temperature data at a preset frequency; comparing the collected temperature data with the safe target temperature range and making temperature difference judgment: lower than the lower limit of the range is determined as low temperature, higher than the upper limit of the range is determined as high temperature, and within the range is determined as temperature meeting the requirements; starting the semiconductor or micro heating and refrigeration elements to control the medicine liquid in the medicine liquid container according to the temperature difference judgment result: when heating, the semiconductor or micro heating element in the container warms up the medicine liquid through heat conduction; when refrigerating, the semiconductor or micro refrigeration element in the container cools down the medicine liquid through heat absorption, and a matching micro cooling fan is started synchronously; in the heating or refrigerating process, the temperature sensor measures the temperature of the medicine liquid in real time and implements temperature control intervention.

4. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 3, characterized in that, The respiratory parameter synchronous monitoring unit is also used for: firstly embedding the micro airflow sensor in series in the pipeline between the patient breathing mask and mouthpiece and the aerosol output end, and then connecting the micro pressure sensor in parallel through a branch pipeline into the pipeline between the breathing mask and mouthpiece and the aerosol output end; when the patient is treated by aerosol, the micro airflow sensor and the micro pressure sensor collect patient respiratory airflow signals and pressure signals in real time; The airflow signal is a signal that is captured in real time according to the respiratory action of the patient, and the flow rate and direction of the airflow change; when the patient inhales, the airflow flows from the atomizer pipeline to the airway of the patient, the micro airflow sensor detects the positive flow rate, and outputs a positive current and voltage signal that changes with the inhalation strength; when the patient exhales, the airflow flows reversely from the airway of the patient to the outside, the micro airflow sensor detects the negative flow rate, and outputs a corresponding negative electric signal; The pressure signal is a signal that is captured synchronously according to the pressure fluctuation in the airway of the patient, and corresponds to the airflow signal; when the patient inhales, if the pressure in the airway is lower than the atmospheric pressure, the micro pressure sensor outputs a negative pressure signal; when the patient exhales, if the pressure in the airway is higher than the atmospheric pressure, the micro pressure sensor outputs a positive pressure signal; Meanwhile, the micro airflow sensor and the micro pressure sensor have the same collection frequency, and the collected airflow signal and pressure signal are converted into physical quantities; The respiratory frequency, tidal volume and inhalation and exhalation time ratio are calculated according to the physical quantities of the airflow signal and the pressure signal; The calculation of the respiratory frequency includes respiratory cycle identification, cycle number statistics and frequency conversion; the calculation of the tidal volume includes inhalation stage definition and flow rate integral calculation; and the calculation of the inhalation and exhalation time ratio includes total time of a single respiratory cycle, inhalation time, exhalation time and inhalation and exhalation ratio calculation. Finally, the respiratory parameter data of the patient in the atomization process is obtained.

5. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 4, characterized in that, The airway abnormality monitoring unit is further configured to: fix a high-sensitivity microphone on the outside of a patient's breathing mask or beside a mouthpiece; when the patient is undergoing atomization treatment, the high-sensitivity microphone continuously collects sound signals at a high-frequency sampling rate, and the collected sound signals are preprocessed, including noise reduction and purification; after the preprocessing, feature recognition is performed, including cough signal recognition and wheezing signal recognition, the detection features of the cough signal being signal intensity peak value, duration and signal starting point, and the detection features of the wheezing signal being frequency stability and cycle correlation; the sound signals after the feature recognition are subjected to stimulation judgment, and the stimulation degree is classified according to the judgment result, including mild stimulation, moderate stimulation and severe stimulation; wherein the mild stimulation is 2-3 times of cough within 1 minute, no wheezing, and the respiratory parameters are within a slight fluctuation range; the moderate stimulation is 4-5 times of cough within 1 minute, or short wheezing, the wheezing time is between 10-20 seconds, and the respiratory frequency is increased by ≥5 times per minute; and the severe stimulation is ≥6 times of cough within 1 minute, or continuous wheezing, the wheezing time is ≥20 seconds, the tidal volume is decreased by ≥20%, and accompanied by rapid breathing; finally, the abnormal stimulation of the airway is judged.

6. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 5, characterized in that, The atomization parameter intelligent adjustment unit is further configured to: the dynamic adjustment process of the piezoelectric ceramic atomization assembly is as follows: first, the respiratory frequency data of the patient, the drug characteristic data and the airway abnormality monitoring data are confirmed; wherein the respiratory rhythm matched with the atomization parameters is confirmed according to the respiratory frequency data; the particle size and rate reference are confirmed according to the drug characteristic data; and whether to perform dynamic adjustment is confirmed according to the airway abnormality monitoring data; First, according to the target particle diameter, the vibration frequency of the piezoelectric ceramic atomization assembly is adjusted, wherein if particle reduction is performed, the vibration frequency is increased; if particle enlargement is performed, the vibration frequency is decreased; After the vibration frequency adjustment is completed, the atomization rate adjustment is performed, wherein if the rate is increased, the driving voltage is increased; if the rate is decreased, the driving voltage is decreased; Finally, according to the vibration frequency and the atomization rate, the drug liquid pushing speed of the infusion pump is matched; The dynamic adjustment process of the airflow type atomization assembly is as follows: First, the patient's breathing frequency data, drug characteristic data and airway abnormality monitoring data are confirmed; Among them, the breathing strength of the airflow matching is confirmed according to the breathing frequency data; the airflow pressure and flow rate reference are confirmed according to the drug characteristic data; whether to perform dynamic adjustment is confirmed according to the airway abnormality monitoring data; According to the airflow pressure and flow rate reference, the air speed and particle size are synchronized, wherein if the rate is increased and the particle is reduced, the airflow pressure is increased and the airflow flow rate is increased; if the rate is decreased and the particle is increased, the airflow pressure is decreased and the flow rate is decreased; When the rate is increased or decreased, the channel opening of the drug liquid is automatically increased or decreased; At the same time, the air source pressure is controlled during the adjustment process, wherein if the air source pressure fluctuation is monitored, the pressure valve is automatically opened and the air flow is supplemented; if the patient's breathing frequency is accelerated, the flow rate is increased and the breathing rhythm is matched; if the drug liquid viscosity is increased, the pressure is appropriately increased; According to the control result, the dynamic adjustment result of the airflow type atomization assembly is obtained.

7. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 6, characterized in that, The respiratory and atomization collaborative drug delivery unit is also used to: First, the patient's breathing cycle data is confirmed, wherein the breathing cycle signal is collected, and the breathing cycle stage is divided according to the characteristics of the airflow signal and the pressure signal in the breathing cycle signal, and the inspiratory initial stage, the inspiratory middle stage, the inspiratory terminal stage and the expiratory stage are obtained after division; The patient's basic information, drug characteristics, airway stimulation results, atomization assembly type and initial power reference data are retrieved, and the basis for power adjustment is constructed; According to the divided breathing cycle stage and the basis for power adjustment, the power adjustment instruction of the piezoelectric ceramic atomization assembly and the airflow type atomization assembly is generated; Among them, the power adjustment instruction is to adjust the voltage of each breathing cycle stage; When the power is adjusted, the patient's breathing frequency is monitored in real time, and the fluctuating breathing frequency is corrected, the breathing cycle is adjusted after correction, and the power adjustment instruction is adjusted; After the adjustment is completed, the adjustment instruction is generated, and the generated instruction is format adapted and instruction synchronized.

8. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 7, characterized in that, The multi-source data fusion management unit is also used to: The patient's entire treatment process data is divided into pre-treatment preparation data, dynamic data during treatment and summary data after treatment; Among them, the pre-treatment preparation data is obtained from the basic information and safety temperature confirmation unit; the dynamic data during treatment is obtained from the temperature control unit, the breathing parameter synchronous monitoring unit, the airway abnormality monitoring unit, the atomization parameter intelligent adjustment unit and the respiratory and atomization collaborative drug delivery unit; the summary data after treatment includes the treatment core index, the abnormal time summary and the final parameter state; The obtained whole treatment process data is preprocessed, including data cleaning, standardization processing and structured classification. The structured classification is classified according to the data type, including basic file set, time series data set and time set. The divided data set is analyzed, including safety analysis, effectiveness analysis and adaptability analysis. The safety analysis includes airway stimulation traceability and parameter compliance check; the effectiveness analysis includes drug utilization efficiency evaluation and treatment effect correlation; and the adaptability analysis includes individual parameter adaptation degree and dynamic adjustment effectiveness. According to the fusion analysis result, three-level feedback is carried out, including real-time feedback, treatment summary and historical comparison. The real-time feedback includes abnormal early warning and adjustment suggestion push; the treatment summary includes treatment process report generation and effect evaluation conclusion generation; and the historical comparison includes quality trend analysis and group characteristic summary. Finally, adjustment suggestions are generated according to the three-level feedback data, including subsequent treatment parameter optimization suggestion, adjustment rule improvement suggestion and clinical operation suggestion.

9. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 8, characterized in that, The multi-source data fusion management unit further comprises: The calculation formula of the treatment effect comprehensive index is as follows: Wherein, E is the treatment effect comprehensive index, the range is 0 to 100, the higher the value, the better the treatment effect; RF is the respiratory rate stability parameter, which represents the coefficient of variation of respiratory rate in the treatment process, unit is dimensionless, calculation method is standard deviation of respiratory rate divided by average respiratory rate, reflecting the stability of respiratory rhythm; TV is the tidal volume improvement parameter, which represents the relative increment of average tidal volume in the treatment process and the baseline tidal volume before treatment, unit is percentage, calculation method is (average tidal volume in treatment-baseline tidal volume before treatment) / baseline tidal volume before treatment×100%, reflecting the improvement degree of lung ventilation function; AI is an airway irritation degree parameter, representing the weighted average of the irritation degree classification detected by the airway abnormality monitoring unit during treatment, ranging from 0 to 1, the lower the value, the lighter the airway irritation, the calculation method is to multiply the occurrence times of mild irritation, moderate irritation and severe irritation by weights 0.2, 0.5 and 0.8 respectively and then sum them up; AR is an atomization parameter adjustment effectiveness parameter, representing the ratio of the adjustment times of the atomization parameter intelligent adjustment unit to the total treatment time, unit: times / min, reflecting the dynamic response ability of the atomization system to the patient's breathing state, AR0 is the baseline value of the atomization parameter adjustment effectiveness parameter, unit: times / min; k1, k2, k3, k4 are weight coefficients, corresponding to the weighted influence of the respiratory rate stability parameter, the tidal volume improvement parameter, the airway irritation degree parameter and the atomization parameter adjustment effectiveness parameter respectively, ranging from 0 to 1, and satisfying k1+k2+k3+k4=1, determined by machine learning model training from historical treatment data; T is the actual average temperature of the liquid medicine during treatment, unit: Celsius, collected by the temperature sensor of the temperature control unit; T0 is the safe target temperature of the atomized medicine, unit: Celsius, determined by the basic information and safety temperature confirmation unit; |T-T0| is the absolute difference between the actual temperature and the target temperature, unit: Celsius, used to quantify the influence of the deviation of temperature control on the treatment effect; According to the calculated treatment effect comprehensive index E, the corresponding treatment effect level is determined by comparing with the pre-set mapping relationship between the treatment effect comprehensive index and the treatment effect level, the level includes four levels: excellent, good, medium and poor, among them, E≥80 is excellent, 60≤E≤80 is good, 40≤E≤60 is medium, E<40 is poor; The determined treatment effect level and treatment effect comprehensive index are transmitted to the multi-source data fusion management unit for real-time feedback, treatment summary and historical comparison; If the treatment effect level is medium or poor, optimization suggestions are generated, including specific parameter suggestions for adjusting the atomization rate, particle size or liquid medicine temperature, and the optimization suggestions are pushed to the medical staff operation interface; After the treatment is completed, the treatment effect comprehensive index and the optimization suggestions are stored in the patient's treatment file for subsequent treatment scheme optimization and historical data analysis.

10. The multi-source data based respiratory medical temperature-control nebulization administration system according to claim 9, wherein, It also includes an intelligent dose optimization module, which is used to perform the following operations: Obtain the basic information of the patient from the basic information and safety temperature confirmation unit, including age, weight, height, respiratory department related medical history and drug characteristics of the atomized medicine; Extract the dynamic data during treatment from the multi-source data fusion management unit, including respiratory rate, tidal volume, airway irritation degree and atomization parameter adjustment data; According to the patient's basic information and dynamic data during treatment, an individualized dose optimization model is constructed, which considers the patient's physiological characteristics, respiratory status and drug characteristics to generate a recommended atomized medicine dose range; Before the treatment starts, according to the patient's weight and respiratory department related medical history, combined with the drug characteristics of the atomized medicine, the initial atomization dose range is preset, and the initial dose range is submitted to the medical staff for manual confirmation; During the treatment, the respiratory parameters collected by the real-time monitoring unit, including the respiratory rate and the tidal volume, and the airway irritation degree detected by the airway abnormality monitoring unit are monitored synchronously; If the respiratory rate is detected to be higher than the preset threshold of 10 times per minute, or the tidal volume is detected to be decreased by more than 15%, or the airway irritation degree is detected to be moderate or severe, the dose adjustment mechanism is triggered; wherein the dose adjustment mechanism includes: according to the increase degree of the respiratory rate, appropriately reducing the atomization rate to reduce the airway irritation; according to the decrease degree of the tidal volume, appropriately increasing the particle size to improve the drug deposition efficiency; according to the airway irritation degree, suspending the atomization for 10-20 seconds and re-evaluating the respiratory state; during the dose adjustment process, whether the liquid temperature is within the safe target temperature range is monitored in real time, if the liquid temperature deviates from the safe target temperature range, the dose adjustment is suspended and the temperature control intervention of the temperature control unit is preferentially executed; after the adjustment is completed, a new recommended dose range is generated, and the adjusted dose parameters and the adjustment reason are recorded to the multi-source data fusion management unit; the adjusted dose range is pushed to the medical staff operation interface, and the corresponding power adjustment instruction is generated through the respiratory and atomization collaborative drug delivery unit to ensure that the atomization parameters are synchronized with the adjusted dose range; After the treatment is completed, the records of the entire dose optimization process, including the initial dose range, the adjustment times, the adjusted dose range and the adjustment reason, are stored to the treatment archive of the patient; If the treatment effect comprehensive index of the treatment effect quantitative evaluation module is lower than 60, the effectiveness of the dose adjustment is further analyzed, and the dose optimization suggestion for the next treatment is generated, including the adjustment amplitude and the adjustment frequency of the recommended dose range.

Images